Results 151 to 160 of about 6,942 (191)

Weekly dihydroartemisinin-piperaquine versus monthly sulfadoxine-pyrimethamine for malaria chemoprevention in children with sickle cell anaemia in Uganda and Malawi (CHEMCHA): a randomised, double-blind, placebo-controlled trial.

Lancet Infect Dis
Idro R, Nkosi-Gondwe T, Opoka R, Ssenkusu JM, Dennis K, Tsirizani L, Akun P, Rujumba J, Nambatya W, Kamya C, Phiri N, Joanita K, Komata R, Innussa M, Tenywa E, John CC, Tarning J, Denti P, Wasmann RE, Ter Kuile FO, Robberstad B, Phiri KS.   +21 more
europepmc   +1 more source

Randomized Field Trial to Assess the Safety and Efficacy of Dihydroartemisinin-Piperaquine for Seasonal Malaria Chemoprevention in School-Aged Children in Bandiagara, Mali. [PDF]

J Infect Dis
Traore K, Coulibaly D, Kone AK, Guindo B, Traore S, Kouriba K, Djimde M, Thera MA.   +7 more
europepmc   +1 more source

The effect of intermittent preventive treatment for malaria with dihydroartemisinin-piperaquine on vaccine-specific responses among schoolchildren in rural Uganda (POPVAC B): a double-blind, randomised controlled trial.

Lancet Glob Health
Zirimenya L, Natukunda A, Nassuuna J, Nkurunungi G, Zziwa C, Ninsiima C, Kukundakwe C, Nankabirwa CM, Katushabe C, Namusobya LK, Oduru G, Kabami G, Kabali J, Kayiwa J, Kabagenyi J, van Dam GJ, Corstjens PLAM, Cose S, Wajja A, Staedke SG, Kaleebu P, Elliott AM, Webb EL, POPVAC trial team.   +23 more
europepmc   +1 more source

Chemoprevention for malaria with monthly intermittent preventive treatment with dihydroartemisinin-piperaquine in pregnant women living with HIV on daily co-trimoxazole in Kenya and Malawi: a randomised, double-blind, placebo-controlled trial. [PDF]

Lancet
Barsosio HC, Madanitsa M, Ondieki ED, Dodd J, Onyango ED, Otieno K, Wang D, Hill J, Mwapasa V, Phiri KS, Maleta K, Taegtmeyer M, Kariuki S, Schmiegelow C, Gutman JR, Ter Kuile FO.   +15 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Dihydroartemisinin–Piperaquine Failure in Cambodia

New England Journal of Medicine, 2014
This letter suggests that rising treatment failures and parasite clearance times and decreasing piperaquine sensitivity 3 years after widespread introduction of artemisinin–piperaquine indicate rapidly emerging resistance to both artemisinin and piperaquine.
Chanthap Lon, David L Saunders, Pattaraporn Vanachayangkul   +2 more
exaly   +2 more sources

Efficacy of dihydroartemisinin/piperaquine in patients with non-complicated Plasmodium falciparum malaria in Yaoundé, Cameroon

Journal of Antimicrobial Chemotherapy, 2021
International audienceBackground: Dihydroartemisinin/piperaquine is increasingly used for the treatment of uncomplicated Plasmodium falciparum malaria in Africa.
Isabelle Morlais, Antoine Berry, Melissa Mairet-Khedim   +2 more
exaly   +2 more sources

Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunate-mefloquine in falciparum malaria: an open-label randomised comparison [PDF]

Lancet, The, 2006
BACKGROUND: Artemisinin-based combinations are judged the best treatments for multidrug-resistant Plasmodium falciparum malaria. Artesunate-mefloquine is widely recommended in southeast Asia, but its high cost and tolerability profile remain obstacles to
Kasia Stępniewska, Nicholas White, Frank Smithuis   +2 more
exaly   +2 more sources

Impact of Dolutegravir-Based Antiretroviral Therapy on Piperaquine Exposure following Dihydroartemisinin-Piperaquine Intermittent Preventive Treatment of Malaria in Pregnant Women Living with HIV [PDF]

Antimicrobial Agents and Chemotherapy, 2022
Dihydroartemisinin-piperaquine, an artemisinin-based combination therapy, has been identified as a promising agent for intermittent preventive treatment of malaria in pregnancy.
Clifford George Banda, Gary Maartens, Joel Tarning   +2 more
exaly   +2 more sources